Cost Effectiveness Analysis (CEA) of Nivolumab in 2nd Line Non-Small Cell Lung Cancer (NSCLC) with Non-Squamous Histology (NSQ) Using A Mixed Comparator of Docetaxel and Pemetrexed in An Australian Setting

Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.205
https://www.valueinhealthjournal.com/article/S1098-3015(17)30539-9/fulltext
Title : Cost Effectiveness Analysis (CEA) of Nivolumab in 2nd Line Non-Small Cell Lung Cancer (NSCLC) with Non-Squamous Histology (NSQ) Using A Mixed Comparator of Docetaxel and Pemetrexed in An Australian Setting
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30539-9&doi=10.1016/j.jval.2017.08.205
First page : A434
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 185
Categories :
Tags :
Regions :
ViH Article Tags :